Therefore, while follow‐up fibroblast testing cannot definitively distinguish between CHIP and constitutional mosaicism to establish the origin of the TP53 PV, it can provide additional information that, when considered in context of clinical factors such as age and cancer history, informs screening and management approaches. This evidence concerns the gene TP53 and cancer.